Dimerix is a clinical-stage biopharmaceutical company, with a portfolio of drug candidates for inflammatory diseases, including kidney and respiratory diseases.

Dimerix' lead candidate is in Phase 3 clinical trials for a rare type of kidney disease. Dimerix encourages collaboration and is well positioned to discuss partnering and product development.

About ACTION3 Phase 3 Clinical Trial
ACTION3 Phase 3 FSGS Clinical Study

ACTION3 Phase 3 FSGS Clinical Study

The purpose of the ACTION3 study is to determine whether the investigational medication DMX-200 is effective and safe in treating a rare kidney condition called Focal Segmental Glomerulosclerosis (FSGS).

Find out more
Product Pipeline

Product Pipeline

Dimerix develops new therapies through the clinic to commercialization. Our lead product is DMX-200 for FSGS kidney disease, currently in a Phase 3 clinical trial.

Find out more